Knome Teams with Omixon to Provide Whole Genome, Exome HLA Typing | GenomeWeb

NEW YORK (GenomeWeb News) – Knome has announced that its services division will now offer Omixon's targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines.

Omixon CEO Attila Berces said in a statement that the HLA typing service should help pharmaceutical companies that utilize Knome's services to identify drug response biomarkers, "shorten the time to approval, and reduce the risk of late-stage failures."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.